SUPN

Insider Trades

Name	Value	Action	Price	Current Price
Bhatt Padmanabh P.Sr. VP Of IP, CSO $339k6.8k shares SellMar 18, 2026 $49.55 --
Bhatt Padmanabh P.Sr. VP Of IP, CSO $21k412 shares SellMar 18, 2026 $50.48 --
Bhatt Padmanabh P.Sr. VP Of IP, CSO $1.4M27.7k shares SellMar 17, 2026 $49.95 --
Bhatt Padmanabh P.Sr. VP Of IP, CSO $1.1M22.3k shares SellMar 17, 2026 $50.73 --
Bhatt Padmanabh P.Sr. VP Of IP, CSO $1.7M34.1k shares SellMar 16, 2026 $50.18 --
Bhatt Padmanabh P.Sr. VP Of IP, CSO $802k15.9k shares SellMar 16, 2026 $50.49 --

News

globenewswire.comSupernus Pharmaceuticals to Participate in June Investor Conferencesglobenewswire.comMay 27

seekingalpha.comSupernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 13

fool.comWhat to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Yearfool.comMay 12

globenewswire.comSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conferenceglobenewswire.comMay 6

Trade SUPN

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

CEO: Jack A. Khattar
IPO Date: May 1, 2012

Market Data

Open: $45.05
High: $45.73
Low: $44.64
Volume: 574.1K
52W High: $59.68
52W Low: $30.83

Valuation

Market Cap: $2.6B
Enterprise Value: $2.5B

Financials

Free Cash Flow: $46M
Revenue: $719M
Net Income: $-39M
Cash: $128M
Debt: $41M

Events

EarningsAug 4

EPS est. 0.455